Literature DB >> 14732173

P53 and breast cancer.

D Ziyaie1, T R Hupp, A M Thompson.   

Abstract

p53 mutation is the most common genetic abnormality found so far in human cancer, and in breast cancer p53 mutation/alteration is seen in up to 50% of primary carcinomas. Together with the increasing knowledge of the characteristics and understanding of the role of p53 over the last two decades, attention in recent years has been focused on how this knowledge can be used in clinical settings for patient care and management in terms of analyzing p53 as a potential marker for studying the relationship between p53 expression and tumour development, progression and outcome; and designing alternative treatment strategies specifically aimed at restoring normal p53 function.

Entities:  

Year:  2000        PMID: 14732173     DOI: 10.1054/brst.2000.0199

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  9 in total

1.  Primary squamous cell carcinoma of the endometrium unrelated to human papilloma virus: a molecular study.

Authors:  Giovanna Giordano; Silvia Pizzi; Cinzia Azzoni; Lorena Bottarelli; Tiziana D'Adda
Journal:  Pathol Oncol Res       Date:  2013-02-21       Impact factor: 3.201

2.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

3.  Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines.

Authors:  A A Liem; M V C L Appleyard; M A O'Neill; T R Hupp; M P Chamberlain; A M Thompson
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 4.  99mTc-MIBI in the evaluation of breast cancer biology.

Authors:  Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-23       Impact factor: 9.236

5.  Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring.

Authors:  H M Ball; T R Hupp; D Ziyaie; C A Purdie; N M Kernohan; A M Thompson
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

6.  Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.

Authors:  G Nicoll; D N Crichton; H E McDowell; N Kernohan; T R Hupp; A M Thompson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

7.  MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.

Authors:  Fiona E M Paulin; Mary O'Neill; Gillian McGregor; Andrew Cassidy; Alison Ashfield; Clinton W Ali; Alastair J Munro; Lee Baker; Colin A Purdie; David P Lane; Alastair M Thompson
Journal:  BMC Cancer       Date:  2008-10-01       Impact factor: 4.430

8.  The concept of radiation-enhanced stem cell differentiation.

Authors:  Adam A Mieloch; Wiktoria M Suchorska
Journal:  Radiol Oncol       Date:  2015-08-21       Impact factor: 2.991

9.  TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET).

Authors:  Geraldine H Chang; Razelle Kurzrock; Lisa Tran; Maria Schwaederle; Carl K Hoh
Journal:  Oncotarget       Date:  2018-02-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.